

1 **Original Manuscript**

2 **A Genetic Perspective on Diabetic Complications: A**

3 **Mendelian Randomization Study on the Increased**

4 **Risk of Cataracts in Type 1 Diabetes**

5 Dongliang Pei<sup>1\*</sup>, Shuyan Wang<sup>1</sup>, Yuan Wang<sup>1</sup>, Chenmin Sun<sup>1</sup>

6 <sup>1</sup>Department of Anesthesiology, Tongren Hospital, Shanghai Jiao Tong University

7 School of Medicine, China.

8 \*Corresponding author: [ketchup@foxmail.com](mailto:ketchup@foxmail.com)

9

## 10 **Abstract**

11 **Background:** The well-documented epidemiological link between type 1 diabetes  
12 and cataract is recognized. Yet, the question of a shared genetic foundation for these  
13 conditions, and the potential implication of a causal connection, is still an area of  
14 uncertainty.

15

16 **Methods:** We utilized a two-sample Mendelian randomization approach to extract  
17 and analyze four GWAS datasets from public databases, aiming to elucidate the  
18 causal relationship between Type 1 Diabetes and cataracts. Our study design  
19 incorporated multiple Mendelian randomization methods to assess the influence of  
20 Type 1 Diabetes genetic risk on the susceptibility to cataracts, and employed the MR-  
21 PRESSO global test for the evaluation of horizontal heterogeneity among the results.

22

23 **Results:** Mendelian Randomization analysis has indicated a statistically significant  
24 association between Type 1 Diabetes and an increased risk of cataract development.  
25 All applied Mendelian Randomization methods pointed to a positive causal estimate,  
26 suggesting that Type 1 Diabetes contributes to an elevated risk of cataracts.

27

28 **Conclusion:** This study supports the hypothesis of a causal relationship between Type  
29 1 Diabetes and cataracts. Despite some heterogeneity, all outcomes are positively  
30 aligned, and leave-one-out analysis confirms the robustness of these findings. This  
31 research is significant for understanding the process of cataract prevention and  
32 treatment in patients with Type 1 Diabetes.

33

## 34 **Introduction**

35 Type 1 Diabetes (T1D) represents a chronic condition that affects millions worldwide.

36 The global incidence rate of T1D stands at 15 per 100,000 individuals, with a

37 prevalence of 9.5%[1]. Notably, these rates are experiencing an upward trend[2, 3].

38 Epidemiological investigations have highlighted a significantly elevated risk of

39 cataracts among patients with Diabetes, compared to the general populace[4, 5]. Most

40 research on diabetes-induced cataracts has focused on metabolic mechanisms[6, 7],

41 but often falls short in ruling out potential confounding factors, such as lifestyle

42 elements and genetic predispositions [6]. The extent of genetic linkage between T1D

43 and cataracts, and whether this linkage reflects a causal relationship, remains unclear.

44

45 Mendelian Randomization (MR), utilizing genetic variants as instrumental variables,

46 emerges as a robust strategy for probing the potential causative link between diseases

47 [8, 9]. This methodology circumvents the limitations commonly encountered in

48 traditional observational studies, like confounding variables and reverse causation

49 issues[10]. Our research leverages the two-sample MR approach, drawing on data

50 from two separate Genome-Wide Association Studies (GWAS), to delve into the

51 potential causal nexus between these two conditions. The strength of this approach

52 lies in its use of genetic variations as instrumental variables, which remain unaffected

53 by environmental factors post-birth, thus offering a distinctive lens to comprehend

54 how T1D potentially escalates the risk of cataracts.

55

56 Through this investigation, our objective is to fortify the evidence base for the

57 prevention and management of cataracts in individuals with diabetes, and to offer

58 insights that could guide future research on biological mechanisms and public health  
59 intervention strategies.

60

## 61 **Materials and Methods**

### 62 **Study Design:**

63 This study was conducted in strict adherence to institutional and national ethical  
64 guidelines. The data utilized were sourced from an open-source database, with  
65 original informed consent for the use of this data having been duly obtained by the  
66 respective GWAS teams. It is important to note that the data from the IEU platform  
67 consist of aggregate statistical summaries from GWAS, inherently devoid of any  
68 personally identifiable information, thereby ensuring ethical compliance in the use of  
69 this data.

70

71 This study utilizes the MR approach to investigate the potential causal link between  
72 T1D and cataract risk. We sourced our data from the IEU platform, an open-source  
73 database for GWAS summary data, established by the MRC Integrative Epidemiology  
74 Unit at the University of Bristol, UK[11, 12]. This analysis involved data from  
75 comprehensive European GWAS to examine the potential effects of diabetes-related  
76 genetic variants on cataract development risk. See Fig 1.

77

78 **Fig 1. Design of the Mendelian Randomization Study of T1D and Cataracts.** The instrumental  
79 variable in this Mendelian randomization study was selected based on the hypothesis that it is  
80 associated with T1D but not influenced by confounding variables. The hypothesis posits that this  
81 variable affects the risk of cataracts solely through its relationship with T1D.

82

### 83 **Data Source:**

84 Two independent sets of genetic instrumental variables associated with T1D from  
85 GWAS studies, ebi-a-GCST90018925 with a sample size of 457,695 individuals and  
86 24,182,422 SNPs, and ebi-a-GCST90014023 with a sample size of 520,580  
87 individuals and 59,999,551 SNPs, were extracted. We evaluated their impact on two  
88 cataract outcomes, ebi-a-GCST90018814 with a sample size of 491,877 individuals  
89 and 24,163,031 SNPs, and ebi-a-GCST90038649 with a sample size of 484,598  
90 individuals and 9,587,836 SNPs[13-15], as detailed in Website:  
91 <https://gwas.mrcieu.ac.uk/>

92

### 93 **Data Integration and Processing:**

94 We employed the TwoSampleMR and MRPRESSO R packages for data integration  
95 and analysis. Relevant SNPs for diabetes (exposure) and cataract surgery (outcome)  
96 were extracted using `extract_instruments` and `extract_outcome_data` functions from  
97 the TwoSampleMR package. Data harmonization was achieved using  
98 `harmonise_data`, and linkage disequilibrium issues were managed with `clump_data`.  
99 The MR-PRESSO global test was used to address potential horizontal pleiotropy and  
100 outliers, including global outlier detection, correction, and distortion tests. SNPs  
101 related to outliers were excluded. Various MR methods, like MR Egger, weighted  
102 median, inverse-variance weighted, simple mode, and weighted mode, were utilized  
103 to explore the potential causal relationship between T1D and the need for cataract  
104 surgery. These methods aimed to quantify the effect of genetic predisposition to  
105 diabetes on the likelihood of requiring cataract surgery.  
106 Heterogeneity was examined using the `mr_heterogeneity` function.  
107 Leave-one-out analysis was conducted using the `mr_leaveoneout` function to assess  
108 the robustness of the results.

109 The robustness of the MR-PRESSO test results was evaluated using the `mr_presso`  
110 function.

### 111 **Statistical Analysis:**

112 All analyses were performed using R software (version 4.3.2). The threshold for  
113 significance in MR analyses was set at  $P < 0.05$ . The same significance threshold was  
114 applied to outlier detection and distortion tests in the MR-PRESSO test.

115

## 116 **Results**

117 We utilized `extract_instruments` and `extract_outcome_data` functions to extract  
118 relevant genetic instrumental variables and outcome data. In the data harmonization  
119 phase, linkage disequilibrium (LD) was addressed, and SNPs incompatible with the  
120 outcomes were excluded. Heterogeneity tests were also conducted to assess the  
121 consistency of the genetic instrumental variables in their impact on the outcomes.

122

123 MR analysis indicated a statistically significant association between T1D and two  
124 different cataract outcomes. In the analysis of the `ebi-a-GCST90018814` outcome,  
125 using `ebi-a-GCST90014023` as the exposure data, the inverse-variance weighted  
126 method suggested a causal association ( $b = 0.0132024389$ ,  $p = 9.991590e-05$ ), though  
127 the heterogeneity test showed marginal significant heterogeneity ( $Q_{pval} =$   
128  $0.05240152$ ). When using `ebi-a-GCST90018925` as the exposure data, all MR  
129 methods pointed to a positive causal estimate, suggesting that T1D appears to increase  
130 the risk of cataracts. The p-values for almost all methods were extremely low,  
131 providing strong statistical evidence. The weighted median method showed the  
132 strongest causal association ( $b = 0.04585755$ ,  $p = 1.785003e-07$ ). See Fig 2. Table1.

133 In the analysis of the ebi-a-GCST90038649 outcome, using both ebi-a-  
134 GCST90018925 and ebi-a-GCST90014023 as exposure data showed statistically  
135 significant associations, with the heterogeneity test showing no significant  
136 heterogeneity. This suggests more consistent effects of the genetic instrumental  
137 variables across these two datasets. See Fig 2. Table1.

138

139 **Fig 2. Forest Plot of Four Group Analysis of Two-Sample MR Methods.** (a): ebi-a-  
140 GCST90018925 on ebi-a-GCST90038649 , (b): ebi-a-GCST90014023 on ebi-a-GCST90018814, (c):  
141 ebi-a-GCST90014023 on ebi-a-GCST90018814, (d): ebi-a-GCST90014023 on ebi-a-GCST90018814.  
142 Despite the use of different MR methods potentially leading to varied effect sizes, the smaller standard  
143 errors and narrow confidence intervals signify the statistical validity of these estimates.  
144

145 **Table 1. Two-Sample MR Between Type 1 Diabetes and Cataracts**

| id.exposure            | id.outcome             | method          | nsnp | b        | se       | pval      |
|------------------------|------------------------|-----------------|------|----------|----------|-----------|
| ebi-a-<br>GCST90018925 | ebi-a-<br>GCST90038649 | MR Egger        | 16   | 0.000867 | 0.000447 | 0.073076  |
|                        |                        | Weighted median | 16   | 0.000773 | 0.000343 | 0.024200  |
|                        |                        | IVW             | 16   | 0.000605 | 0.000276 | 0.028573  |
|                        |                        | Simple mode     | 16   | 0.001228 | 0.000677 | 0.089769* |
|                        |                        | Weighted mode   | 16   | 0.000829 | 0.000318 | 0.019834  |
| ebi-a-<br>GCST90018925 | ebi-a-<br>GCST90018814 | MR Egger        | 17   | 0.031537 | 0.016302 | 0.072145* |
|                        |                        | Weighted median | 17   | 0.045862 | 0.008516 | 7.22E-08  |
|                        |                        | IVW             | 17   | 0.046036 | 0.010517 | 1.20E-05  |
|                        |                        | Simple mode     | 17   | 0.057924 | 0.025322 | 0.036120  |
|                        |                        | Weighted mode   | 17   | 0.044869 | 0.008073 | 4.33E-05  |
| ebi-a-<br>GCST90014023 | ebi-a-<br>GCST90018814 | MR Egger        | 76   | 0.012421 | 0.004261 | 4.70E-03  |
|                        |                        | Weighted median | 76   | 0.015327 | 0.003646 | 2.62E-05  |
|                        |                        | IVW             | 76   | 0.013202 | 0.003393 | 9.99E-05  |
|                        |                        | Simple mode     | 76   | 0.000903 | 0.014722 | 0.951261* |
|                        |                        | Weighted mode   | 76   | 0.014151 | 0.003528 | 1.41E-04  |
| ebi-a-<br>GCST90014023 | ebi-a-<br>GCST90038649 | MR Egger        | 78   | 0.000309 | 0.000148 | 0.040659  |
|                        |                        | Weighted median | 78   | 0.000366 | 0.00015  | 0.014693  |
|                        |                        | IVW             | 78   | 0.000305 | 0.000116 | 0.008325  |
|                        |                        | Simple mode     | 78   | 0.00021  | 0.000438 | 0.632663* |
|                        |                        | Weighted mode   | 78   | 0.000284 | 0.000129 | 0.030757  |

146 \*  $pval > 0.05$

147

#### 148 **Heterogeneity Analysis:**

149 The heterogeneity test showed marginal significant heterogeneity ( $Q_{pval} =$   
150  $0.05240152$ ) in the analysis of the ebi-a-GCST90018814 outcome, using ebi-a-  
151 GCST90014023. The MR-PRESSO analysis did not identify any significant outliers,  
152 and the global test indicated no substantial data distortion. However, significant

153 pleiotropy was detected in the analysis of the effect of ebi-a-GCST90018925 on ebi-a-  
154 GCST90018814, with a p-value of 0.021.

### 155 **Sensitivity Analysis:**

156 The leave-one-out sensitivity analysis further confirmed the robustness of our  
157 findings, with no single SNPs significantly altering the overall MR estimates, as  
158 shown in Fig 3.

159

160 **Fig 3. MR Leave-One-Out Sensitivity Analysis for the Impact of T1D on Cataracts.** Each circle  
161 represents the MR analysis outcome for the remaining SNPs, after sequentially excluding each SNP in  
162 turn.  
163

164 The scatter plots collectively demonstrate MR analyses using diverse MR methods, all  
165 indicating a consistent positive causal effect of T1D on the risk of developing  
166 cataracts. The uniform directionality of the SNP effect estimates across different  
167 analytical approaches reinforces the robustness of the causal inference. as shown in  
168 Fig 4.

169

170 **Fig 4. MR Analysis Scatter Plots for T1D and Cataract Risk.** All indicating a consistent positive  
171 causal effect of T1D on the risk of developing cataracts. The uniform directionality of the SNP effect  
172 estimates across different analytical approaches reinforces the robustness of the causal inference.  
173

## 174 **Discussion**

175 This study employed a two-sample MR method to explore the potential causal  
176 relationship between T1D and cataracts. Our findings indicate a significant  
177 association between T1D and cataracts, suggesting a higher incidence of cataracts  
178 among diabetic patients. Although the MR-PRESSO global test detected significant  
179 pleiotropy in the effect of ebi-a-GCST90018925 on ebi-a-GCST90018814 (p-value:



180 0.021), the majority of our results are positive and robust, indicating that this does not  
181 compromise our main findings.

182

183 Diabetes is a metabolic disease where prolonged high blood sugar levels can lead to  
184 various complications. In ophthalmology, diabetes can affect the health of the lens in  
185 multiple ways, including accelerating cataract development through promoting non-  
186 enzymatic glycation reactions and oxidative stress[16-18]. It's reported that the  
187 likelihood of cataracts in diabetic patients is five times higher. The risk is dependent  
188 on the duration of diabetes, the frequency of blood sugar levels exceeding the target  
189 range, and the presence of macular edema[19].

190

191 Patients with T1D have a higher risk of developing cataracts, which is a clouding of  
192 the eye's lens leading to a decrease in vision and can affect the quality of life[19-21].

193 The occurrence of cataracts in diabetic patients is associated with prolonged  
194 uncontrolled high blood sugar and significant fluctuations in blood sugar levels,  
195 leading to osmotic imbalances in the lens. Risk factors for diabetic cataracts include  
196 elevated levels of glycated hemoglobin, diabetic ketoacidosis, and the duration and  
197 control of diabetes. Diabetic cataracts are more common in adolescent females and  
198 develop rapidly, often within weeks or months. The most common type of cataract in  
199 diabetic patients is posterior subcapsular cataracts[22].

200

201 MR is a research method that uses genetic variations as instrumental variables to  
202 examine the causal effects of modifiable exposures on diseases. Based on Mendel's  
203 laws of inheritance and instrumental variable estimation, it can infer causal effects in  
204 the presence of unobserved confounders[8]. The term was initially proposed by Gray

205 and Wheatley in 1991 and has been applied in studies using genetic variants reliably  
206 associated with modifiable exposures[23]. Compared to observational studies, this  
207 method is less likely to be affected by confounders or reverse causation[24]. MR has  
208 been applied in various fields, including medicine and public health, for causal  
209 inference. It has been used in studies concerning cancer, cardiovascular diseases, and  
210 more.

211

212 The study utilized Genome-Wide Association Study (GWAS) data from East Asian  
213 populations to conduct a MR analysis of Type 2 Diabetes and cataracts, integrating  
214 GWAS data with expression quantitative trait loci (eQTL) data. This identified two  
215 candidate functional genes (MIR4453HG and KCNK17), whose expression levels  
216 may be associated with the causal relationship between Type 2 Diabetes and  
217 cataracts[25]. our European study points to different genetic markers, indicating a  
218 complex and diverse genetic landscape influencing the link between diabetes and  
219 cataracts.

220

221 Despite the new insights our study offers into the relationship between T1D and  
222 cataracts, there are limitations. Firstly, our analysis relies on summary data from  
223 public GWAS databases, which may not capture all relevant genetic variations.  
224 Secondly, our analysis includes only data from European populations, limiting its  
225 generalizability.

226

227 Our findings have significant implications for public health strategies. Recognizing  
228 the higher risk of cataract development in T1D patients can promote earlier screening

229 and intervention measures. Moreover, this discovery underscores the importance of  
230 blood sugar control in preventing cataracts in T1D patients.

231

## 232 **Conclusions**

233 The results of this study support the hypothesis of a causal relationship between T1D  
234 and cataracts. Although there is heterogeneity, all outcomes are positive, and the  
235 leave-one plot indicates robust results. Particularly, the MR-PRESSO test results  
236 suggest that this relationship is unlikely to be affected by multidirectional  
237 heterogeneity. The directional consistency of the scatter plots is encouraging, and  
238 these findings are significant for understanding the process of preventing and treating  
239 cataracts in T1D patients.

240

## 241 **Acknowledgements**

242 My heartfelt thanks go to my family and colleagues for their unwavering support and  
243 assistance. Your encouragement and cooperation have been invaluable on my journey.

244

## 245 **References**

- 246 1. Mobasseri M, Shirmohammadi M, Amiri T, Vahed N, Hosseini Fard H,  
247 Ghojazadeh M. Prevalence and incidence of type 1 diabetes in the world: a systematic  
248 review and meta-analysis. *Health Promot Perspect*. 2020;10(2):98-115. doi:  
249 10.34172/hpp.2020.18.
- 250 2. Berhan Y, Waernbaum I, Lind T, Möllsten A, Dahlquist G. Thirty years of  
251 prospective nationwide incidence of childhood type 1 diabetes: the accelerating

- 252 increase by time tends to level off in Sweden. *Diabetes*. 2011;60(2):577-81. doi:  
253 10.2337/db10-0813.
- 254 3. Waernbaum I, Lind T, Möllsten A, Dahlquist G. The incidence of childhood-  
255 onset type 1 diabetes, time trends and association with the population composition in  
256 Sweden: a 40 year follow-up. *Diabetologia*. 2023;66(2):346-53. doi: 10.1007/s00125-  
257 022-05816-0.
- 258 4. Becker C, Schneider C, Aballéa S, Bailey C, Bourne R, Jick S, et al. Cataract  
259 in patients with diabetes mellitus-incidence rates in the UK and risk factors. *Eye*  
260 (Lond). 2018;32(6):1028-35. doi: 10.1038/s41433-017-0003-1.
- 261 5. Klein R, Klein BEK. Epidemiology of Ocular Functions and Diseases in  
262 Persons With Diabetes. In: Cowie CC, Casagrande SS, Menke A, Cissell MA,  
263 Eberhardt MS, Meigs JB, et al., editors. *Diabetes in America*. Bethesda (MD):  
264 National Institute of Diabetes and Digestive and Kidney Diseases (US); 2018.
- 265 6. Mrugacz M, Pony-Uram M, Bryl A, Zorena K. Current Approach to the  
266 Pathogenesis of Diabetic Cataracts. *Int J Mol Sci*. 2023;24(7). Epub 2023/04/14. doi:  
267 10.3390/ijms24076317. PubMed PMID: 37047290; PubMed Central PMCID:  
268 PMCPMC10094546.
- 269 7. Chitra PS, Chaki D, Boiroju NK, Mokalla TR, Gadde AK, Agraharam SG, et  
270 al. Status of oxidative stress markers, advanced glycation index, and polyol pathway  
271 in age-related cataract subjects with and without diabetes. *Exp Eye Res*.  
272 2020;200:108230. Epub 2020/09/16. doi: 10.1016/j.exer.2020.108230. PubMed  
273 PMID: 32931824.
- 274 8. Sanderson E, Glymour MM, Holmes MV, Kang H, Morrison J, Munafò MR,  
275 et al. Mendelian randomization. *Nature Reviews Methods Primers*. 2022;2(1):6. doi:  
276 10.1038/s43586-021-00092-5.

- 277 9. Davies NM, Holmes MV, Davey Smith G. Reading Mendelian randomisation  
278 studies: a guide, glossary, and checklist for clinicians. *Bmj*. 2018;362:k601. Epub  
279 2018/07/14. doi: 10.1136/bmj.k601. PubMed PMID: 30002074; PubMed Central  
280 PMCID: PMC6041728 interests and declare that we have no competing  
281 interests.
- 282 10. Pingault JB, O'Reilly PF, Schoeler T, Ploubidis GB, Rijdsdijk F, Dudbridge F.  
283 Using genetic data to strengthen causal inference in observational research. *Nat Rev*  
284 *Genet*. 2018;19(9):566-80. Epub 2018/06/07. doi: 10.1038/s41576-018-0020-3.  
285 PubMed PMID: 29872216.
- 286 11. Matthew L, Shea JA, Ben E, Tom RG, Gibran H, Edoardo M. The variant call  
287 format provides efficient and robust storage of GWAS summary statistics. *bioRxiv*.  
288 2020:2020.05.29.115824. doi: 10.1101/2020.05.29.115824.
- 289 12. Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, et al. The  
290 MR-Base platform supports systematic causal inference across the human phenome.  
291 *Elife*. 2018;7. doi: 10.7554/eLife.34408.
- 292 13. Chiou J, Geusz RJ, Okino ML, Han JY, Miller M, Melton R, et al. Interpreting  
293 type 1 diabetes risk with genetics and single-cell epigenomics. *Nature*.  
294 2021;594(7863):398-402. doi: 10.1038/s41586-021-03552-w.
- 295 14. Sakaue S, Kanai M, Tanigawa Y, Karjalainen J, Kurki M, Koshihara S, et al. A  
296 cross-population atlas of genetic associations for 220 human phenotypes. *Nat Genet*.  
297 2021;53(10):1415-24. doi: 10.1038/s41588-021-00931-x.
- 298 15. Dönertaş HM, Fabian DK, Valenzuela MF, Partridge L, Thornton JM.  
299 Common genetic associations between age-related diseases. *Nat Aging*.  
300 2021;1(4):400-12. doi: 10.1038/s43587-021-00051-5.

- 301 16. Nawale RB, Mourya VK, Bhise SB. Non-enzymatic glycation of proteins: a  
302 cause for complications in diabetes. *Indian J Biochem Biophys.* 2006;43(6):337-44.
- 303 17. Younus H, Anwar S. Prevention of non-enzymatic glycosylation (glycation):  
304 Implication in the treatment of diabetic complication. *Int J Health Sci (Qassim).*  
305 2016;10(2):261-77.
- 306 18. Ma Y, Cai J, Wang Y, Liu J, Fu S. Non-Enzymatic Glycation of Transferrin  
307 and Diabetes Mellitus. *Diabetes Metab Syndr Obes.* 2021;14:2539-48. doi:  
308 10.2147/dmso.S304796.
- 309 19. Kiziltoprak H, Tekin K, Inanc M, Goker YS. Cataract in diabetes mellitus.  
310 *World J Diabetes.* 2019;10(3):140-53. doi: 10.4239/wjd.v10.i3.140.
- 311 20. Wu J, Zeng H, Xuan R, Lei S, Li J, Lai X, et al. Bilateral cataracts as the first  
312 manifestation of type 1 diabetes mellitus: A case report. *Medicine (Baltimore).*  
313 2018;97(42):e12874. doi: 10.1097/md.00000000000012874.
- 314 21. Niederland T, Futó G, Gál V. [Acute metabolic cataract as a first  
315 manifestation of IDDM in an adolescent girl]. *Orv Hetil.* 1999;140(35):1953-6.
- 316 22. Pollreisz A, Schmidt-Erfurth U. Diabetic cataract-pathogenesis, epidemiology  
317 and treatment. *J Ophthalmol.* 2010;2010:608751. doi: 10.1155/2010/608751.
- 318 23. Smith GD, Ebrahim S. 'Mendelian randomization': can genetic epidemiology  
319 contribute to understanding environmental determinants of disease? *Int J Epidemiol.*  
320 2003;32(1):1-22. doi: 10.1093/ije/dyg070.
- 321 24. Neil MD, Michael VH, George Davey S. Reading Mendelian randomisation  
322 studies: a guide, glossary, and checklist for clinicians. *BMJ.* 2018;362:k601. doi:  
323 10.1136/bmj.k601.
- 324 25. Zhang H, Xiu X, Xue A, Yang Y, Yang Y, Zhao H. Mendelian randomization  
325 study reveals a population-specific putative causal effect of type 2 diabetes in risk of

326 cataract. International Journal of Epidemiology. 2021;50(6):2024-37. doi:

327 10.1093/ije/dyab175.

328

329

330

## 331 **Supporting information**

332 **S1\_File.docx. ebi-a-GCST90018925 on ebi-a-GCST90038649.** the complete set of  
333 scripts and code used in the Mendelian Randomization study examining the effect of  
334 ebi-a-GCST90018925 on ebi-a-GCST90038649, facilitating replication and further  
335 exploration of the study's methodology and findings.

336

337 **S2\_File.docx. ebi-a-GCST90018925 on ebi-a-GCST90018814.** the complete set of  
338 scripts and code used in the Mendelian Randomization study examining the effect of  
339 ebi-a-GCST90018925 on ebi-a-GCST90018814, facilitating replication and further  
340 exploration of the study's methodology and findings.

341

342 **S3\_File.docx. ebi-a-GCST90014023 on ebi-a-GCST90018814.** the complete set of  
343 scripts and code used in the Mendelian Randomization study examining the effect of  
344 ebi-a-GCST90014023 on ebi-a-GCST90018814, facilitating replication and further  
345 exploration of the study's methodology and findings.

346

347 **S4\_File.docx. ebi-a-GCST90014023 on ebi-a-GCST90038649.** the complete set of  
348 scripts and code used in the Mendelian Randomization study examining the effect of  
349 ebi-a-GCST90014023 on ebi-a-GCST90038649, facilitating replication and further  
350 exploration of the study's methodology and findings.






Fig1




Fig2









Fig3

ebi-a-GCST90038649



ebi-a-GCST90018814





Fig4